Pharmacoeconomic evaluation of Ipilimumab (Yervoy®) for the treatment of advanced (unresectable or metastatic) melanoma in adult patients who have received prior therapy.
|31/05/2011||09/06/2011||Full Pharmacoeconomic Evaluation Recommended|
|29/07/2011||02/09/2011||Reimbursement not recommended at the submitted price.|
We cannot recommend reimbursement of Ipilimumab at the submitted price.
The HSE has approved reimbursement following confidential price negotiations.